• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Amgen to Acquire Five Prime Therapeutics for $1.9B

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Reed-Lane Facility Virtual Tour

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Aphena Pharma Solutions

    Adare Pharma Solutions

    Almac Group

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Syngene

    Cytovance Biologics

    Adare Pharma Solutions

    Reed-Lane
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Improving Product Profitability

    Using PAT/QbD/CM as tools to increase profitability of products.

    Improving Product Profitability
    Related CONTENT
    • Strata Oncology Unveils Strata PATH Trial
    • Phlow Corp. and USP Form Alliance
    • Cryoport Launches ESG Program
    • Solid Dose Market Trends
    • Manufacturing Equipment Trends
    Emil Ciurczak, Contributing Editor01.21.21
    Back in 1993, I had the pleasure of owning a Ford SHO (Super High Output). For those of you who are not familiar with the car, it strongly resembles a “normal” Taurus… but, on steroids. It was one of the fastest American cars made (at the time), accelerating from zero to OMG in a few seconds. When my son asked how fast I had ever driven it I simply answered “75 MPH.” A little thing like road construction and laws were involved. [I dreamed of the German Autobahn, but… And 75 MPH was less than halfway up the tachometer.] Why do I mention this “beast?” Well, out current PAT/QbD efforts are almost parallel. In this column, I will explain the benefits of “unleashing the beast” that is QbD.
     
    All the tools, already in hand, used for “normal” PAT/QbD process improvements may also be expanded to increase the profit of almost any product. In addition to “merely” controlling production and assuring continuity and reproducibility of products, the concept may be expanded in all directions. Let’s look at three major places where these tools will help:
     
    1. API synthesis. Yes, the actual chemistry could be and is being helped by continuous processing at some companies (the engineering is simpler than making tablets and such), but I am referring to the particular form of the API: both the co-ion (Na+, Ca2+, etc.) and the polymorphic form are variable. Within our “silo-type” organization [meaning we all do our share, staying in our “own lane,” without consideration or even awareness of the previous or next step in the process], the synthetic organic chemists aim for the highest yields, without consideration of the processability or long-term stability of the final dosage formulation.
     
    If the QbD process were extended to all parts of the process, the people making the API would be privy to the processing characteristics of each type or salt or polymorph. So, for example, if the formulators were to show better processability (or stability) form “B,” even though form “A” can give a higher yield in the synthesis process, the lower yield would be more than compensated by lower production costs for the final dosage form.
     
    2. Pre-Formulation/Formulation. The (stated) purpose of normal pre-formulation studies are to screen potential incompatibilities between the API(s) and individual excipients. However, the traditional methodology of making 1:1 mixes of the API and a single excipient only gives limited information. The reason for such limited data generation is the labor-intensive format: a number of these 1:1 mixtures are made, placed into temperature/humidity cabinets (RT, 500 C, 350C/70%RH, etc.).  At specified time periods (4 weeks, 8 weeks, 12 weeks, etc.), a set of mixtures is analyzed for breakdown products.
     
    The resultant data only shows whether the API is compatible with that one excipient. The interactions between the API and multiple excipients (mirroring what occurs in production and the final dosage form) are not explored, just extrapolated. Ideally, we would perform a true Design of Experiment (DoE), wherein a statistical model is generated with mixes of the API and several excipients, simultaneously. These data would really, really give the formulators a leg up on designing a final formulation. So, why isn’t it done?
     
    The time and cost of doing a traditional “sacrifice” of samples at pre-set time points would not be as valuable for several reasons:
     
    a. If we only analyze the samples at four to twelve-week time points, we know that there was some interaction, but we don’t have a relative rate at which the samples began reacting (a little Heisenberg action here).
     
    b. The work involved in the analyses would be expensive and not obtained in a timely fashion. Rapid testing would allow for faster determinations of “better” mixtures.
     
    The answer to the problem would be to proceed and make the “designed” mixtures, but examine them non-destructively, using spectroscopic methods. Equipment exists that can be equipped with (at least) four fiber-optic probes for near-infrared or Raman spectroscopy. If the vials, for example, were in test-tube rack, four-across, they could be taken from the stability chambers, capped (to maintain the humidity levels) and scanned through the base of the vial… then returned to the chambers. This may be repeated daily to limit both the amount of API used and work performed on samples with no reaction(s).
     
    If any one of the vials shows spectral differences, it may be analyzed (there will, of course, be replicates available) and the reaction determined. The benefits of this approach are:
     
    a. The relative rates of any breakdowns can both show the best formulations, but hint at potential expiry dates for final dosage forms.
     
    b. Any potential positive interactions could also be noted. That is the API might interact badly with excipient “A,” but not be affected by a mixture of “A & B.”
     
    c. Various polymorphs and salts could be added to the DoE matrix, further adding to the determination of the “best” formulation possible. In other words, not only would we be testing the drug-excipient interactions, but helping define which form of the drug would be most successful in a dosage form.
     
    3. Stability Extension and Expiry Recalibration. Currently, we use “time-tested” (a.k.a., old-fashioned and “safe”) methods for setting expiration dates and performing stability studies. In most cases, a predetermined number of containers of the finished product are placed on stability (RT and stressful temperature and humidity conditions) and at set times, one container is removed and tests such as assay (including degradation byproducts), physical parameters (i.e., color or hardness), and dissolution profile.
     
    These tests were instituted decades ago, long before concepts (and analytical equipment) commonly applied to PAT and QbD were available. Today, multiple, rapid, and non-destructive tests are widely available for stability testing. When a company is running a successful QbD program, all the parameters are monitored: all the chemical and physical properties of raw materials, intermediates, and finished product.
     
    The very basic tenet of QbD is the “design space,” or the process parameters that may be modified, in situ, to obtain the optimal product. So, for any batch, we have a complete record of the source and attributes of each ingredient and intermediate. So, with more complete stability measurements, these data can be correlated to render a clearer picture of each products status. So, how may this better mousetrap be built?
     
    a. Measure every dosage form. Currently, if we have a 100 tablet or capsule container, we actually only test a portion of the contents. Even performing content uniformity (10 units) and dissolution (6 units), without the need for a retest, that leaves 84 units undisturbed.
     
    Using a non-destructive technique, such as near-infrared or Raman, all 100 units in each bottle (or, every unit in a set of blister packs can be scanned through the plastic) may be scanned. In fact, this scanning may be used as a method for choosing the units for assay or dissolution, allowing potential OOS tablets/capsules to be further assayed by the compendial method.
     
    b. Correlate the number and time of OOS samples with design space. In other words, we can show that Batch “A” has four questionable units at one year, Batch “B” has ten, and so forth. By correlating the production parameters (design space) with the percent good/questionable units, the design space can be modified to improve the stability of the product (we assume the assay and dissolution of the initial finished product already pass QC standards).
     
    c. Cement the design space and assure longer stability. This is one of the great powers of QbD: not only to make a product for release that is within all CPPs (Critical Product Parameters), but can be “fine-tuned” to extend the expiry date. That alone could add $$$$ to the values of a drug. One year longer on the shelf cuts back drastically on recalls and potential OOS findings by the Agency.
     
    And then there are numerous (almost unintended) benefits from this “expended” application and, by adding continuous manufacturing,” we see even more time and cost savings:
     
    1. Any time you can know which combination of parameters will give you extended stability, the additional year (or two) on an expiry date could be worth millions.
     
    2. The information from the pre-formulation studies may be used to optimize the clinical trial samples, giving formulation scientists a “leg-up” on developing the final formulation.
     
    3. If we use continuous manufacturing, the change of design space to assure better stability can be performed with some cost savings:
     
    a. Since smaller batches are needed for CM, the design of experiment can be performed using far, far less of the expensive API (especially if it is not yet made in bulk).
     
    b. Many “batches” of modified product can be made in a single day, not weeks, as cGMP requires “commercial level” batches for a DoE.
     
    c. Time savings are realized for both analyses of numerous batches and cleaning/cleaning validation of the larger equipment between each experimental batch, since CM units need not be disconnected between variation.
     
    d. The increase in stability performance allows companies to fulfill the USFDA Guidance on lifecycle management (2018) [i.e., Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management]. This allows the company to comply and, in the course of better understanding, make a better product at a lower cost.
     
    So, we see that “opening the throttle” on the engine named QbD would lead to better products, time savings, and improved profitability. And, for initiator companies, this would allow a retail price reduction, but still allow for a reasonable profit in the face of generic competition.
    Related Searches
    • Laboratory Testing
    • Analytical Services
    Suggested For You
    Strata Oncology Unveils Strata PATH Trial Strata Oncology Unveils Strata PATH Trial
    Phlow Corp. and USP Form Alliance Phlow Corp. and USP Form Alliance
    Cryoport Launches ESG Program Cryoport Launches ESG Program
    Solid Dose Market Trends Solid Dose Market Trends
    Manufacturing Equipment Trends Manufacturing Equipment Trends
    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    Vetter continues its successful performance at the 2021 CMO Leadership Awards Vetter continues its successful performance at the 2021 CMO Leadership Awards
    FUJIFILM Diosynth Hosts UK PM at COVID Vax Mfg. Site FUJIFILM Diosynth Hosts UK PM at COVID Vax Mfg. Site
    Pfizer, BioNTech to Supply the U.S. with 100mn Additional Doses of COVID-19 Vaccine Pfizer, BioNTech to Supply the U.S. with 100mn Additional Doses of COVID-19 Vaccine
    Anova Enterprises Acquires Corlexia Clinical Services Anova Enterprises Acquires Corlexia Clinical Services
    Thermo Fisher, JW Therapeutics Form CAR-T Partnership in China Thermo Fisher, JW Therapeutics Form CAR-T Partnership in China
    Catalent, Trizell Enter Cell Therapy Deal Catalent, Trizell Enter Cell Therapy Deal
    Immunome, Abzena Enter COVID-19 Antibody Cocktail Agreement Immunome, Abzena Enter COVID-19 Antibody Cocktail Agreement
    UK Secures 40M Doses of Valneva COVID-19 Vax UK Secures 40M Doses of Valneva COVID-19 Vax
    Recipharm, Medspray Launch Resyca JV Recipharm, Medspray Launch Resyca JV

    Related Online Exclusives

    • Analytical Services | Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development | Fill/Finish
      A New Era of Vaccine and Biologic Drug Development

      A New Era of Vaccine and Biologic Drug Development

      As a result of COVID-19, unprecedented investments in vaccines, diagnostics, and treatments have had a tremendous impact on the Biotechnology industry.
      Kristin Brooks, Managing Editor 01.12.21

    • Analytical Services | Biologics, Proteins, Vaccines | Drug Development | Drug Discovery | Laboratory Testing
      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      Responding to demand for challenging assays and custom solutions required for complex molecules, biologics, vaccines and other innovative therapies.
      Kristin Brooks, Contract Pharma 06.22.20

    • Analytical Services | Bioanalytical Services | Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development | Formulation Development
      Contract Pharma’s 20th Anniversary Series: Ajinomoto Bio-Pharma

      Contract Pharma’s 20th Anniversary Series: Ajinomoto Bio-Pharma

      David Enloe of Ajinomoto Bio-Pharma Services shares his perspective on market changes over the years and the evolution of more integrated outsourcing
      Kristin Brooks, Contract Pharma 11.11.19


    • Extractables and Leachables | Laboratory Testing
      The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?

      The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?

      Andrew Kolbert of Avomeen discusses FDA oversight of E&L testing, complications that arise, and the expertise needed to keep up with changing quality standards
      Kristin Brooks, Contract Pharma 07.11.19

    • Analytical Services | Bio News | Bioanalytical Services | Breaking News | Industry News | Information Technology | Logistics | R&D | Supply Chain | Validation
      Blockchain Technology: How Much Money Will It Save?

      Blockchain Technology: How Much Money Will It Save?

      GlobalBlock Co-Founder, David Thomas, shares insight about the future of Blockchain Technology in the Pharmaceutical industry
      Betsy Louda, Associate Editor 01.08.19

    • Analytical Services | Bio News | Breaking News | Clinical Trials | CRO News | Drug Discovery | Laboratory Testing
      Streamlining the Clinical Process

      Streamlining the Clinical Process

      Richard Young, vice president at Veeva, shares insight on what companies can do to further expedite the clinical process
      07.12.18


    • Bioanalytical Services | Drug Development | Laboratory Testing
      Biologic Sample Management in R&D

      Biologic Sample Management in R&D

      Vyas of PAREXEL discusses the significance of biologic samples, sample management challenges and the regulatory implications
      Kristin Brooks, Managing Editor 02.15.18

    • Analytical Services | Bio News | Bioanalytical Services | Industry News | R&D
      Weill Cornell Joins the TriNetX Network

      Weill Cornell Joins the TriNetX Network

      The move makes their total patient population of over two million available for query through the platform
      02.08.18

    • Analytical Services | Bioanalytical Services | Biosimilars | Drug Development | Drug Discovery | Inspections | Laboratory Testing | Preclinical Outsourcing | QA/QC | Regulatory Affairs | Serialization
      2015 Contracting & Outsourcing Wrap-up

      2015 Contracting & Outsourcing Wrap-up

      A huge success, with another year of record attendance, sold-out exhibit hall, and a great line up of informative sessions
      Kristin Brooks, Contract Pharma 09.30.15


    • Analytical Services | Bioanalytical Services | Bioassay Development | Capsules | Chemistry | Clinical Trials | Drug Development | Excipients | Formulation Development | GMPs/GCPs | Industry News | Inspections | Laboratory Testing | Methods Development | Process Development | Regulatory Affairs | Solid Dosage/Semi-solids | Toxicology

      Molecular Profiles Hosts Bioavailability Event

      Biannual event attracts scientists, executives
      Gil Roth 02.11.14

    • APIs | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Industry News | Information Technology | Inspections | Laboratory Testing | Lyophilization | Methods Development | Process Development | QA/QC | Regulatory Affairs | Serialization | Supply Chain | Validation

      FDA Publishes Report on GDUFA

      First-year goals met
      Gil Roth 02.05.14

    • APIs | Aseptic Processing | Capsules | Cleaning Validation | Clinical Trial Materials | Clinical Trials | Extractables and Leachables | Facilities | Fill/Finish | Formulation Development | GMPs/GCPs | Industry News | Information Technology | Inspections | Laboratory Testing | Lyophilization | Methods Development | Microbiology | Process Development | QA/QC | Regulatory Affairs | Serialization | Solid Dosage/Semi-solids | Supply Chain | Validation

      European Medicines Agency Reveals New Structure

      EMA reorganizes to cover drugs' lifecycles
      Gil Roth 09.16.13


    • Analytical Services | Bioanalytical Services | Bioassay Development | Chemistry | Laboratory Testing | Microbiology | Preclinical Outsourcing | Toxicology

      WIL Research Acquires Ricerca Lyon

      CEO David Spaight explains geographic, capacity play
      Gil Roth 08.26.13

    • Clinical Trials | CRO News | Drug Discovery | Laboratory Testing | Preclinical Outsourcing | Validation

      CrownBio-PRECOS Acquisition

      Crown Bioscience's president talks about this preclinical play
      Kristin Brooks 08.21.13

    • Analytical Services | Bioanalytical Services | Bioassay Development | Capsules | Cleaning Validation | Extractables and Leachables | Facilities | Fill/Finish | Formulation Development | GMPs/GCPs | Inspections | Laboratory Testing | Lyophilization | Methods Development | Process Development | Process Validation | QA/QC | Solid Dosage/Semi-solids | Toxicology | Validation | Vials

      Manufacturing Equipment Trends

      Industry perspective from suppliers and manufacturers
      Kristin Brooks, Associate Editor 03.07.12

    Trending
    • Catalent Acquires Delphi Genetics
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • Matica Biotechnology Breaks Ground On Cell And Gene Therapy Site
    • Celonic Group Announces Plans For New Facility In Switzerland
    • BMS Expands Cell Therapy Manufacturing Capabilities
    Breaking News
    • Amgen to Acquire Five Prime Therapeutics for $1.9B
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    • CureVac, Novartis Ink COVID Vax Mfg. Pact
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Statins May Contribute to Vascular Calcification by Inhibiting Vitamin K-Dependent Proteins
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Maroon Group Acquires Cary Company's Raw Materials, Specialty Chemicals Distribution Business
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    EchoNous Expands Its Kosmos Hardware Platform
    Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib
    Europe's Cross-Border Medtech Deal Activity Rises in Q4 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Amgen to Acquire Five Prime Therapeutics for $1.9B
    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    CureVac, Novartis Ink COVID Vax Mfg. Pact
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Establishes Equity and Engagement Center of Excellence
    L'Oreal On How It Will Shape Beauty's Future at Today's Transparency Summit
    C.O. Bigelow Earns Praise as NYC's Oldest Family-Run Apothecary
    Happi

    Latest Breaking News From Happi

    China To End Animal Testing for Imported 'Ordinary' Cosmetics
    Avon Launches Vegan Skin Care Line
    Inolex Appoints VP Marketing
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Springfield Solutions highlights digital label embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints Managing Director, China and Asia Pacific
    Full-Year Sales Down 12 Percent at Zimmer Biomet
    Lincotek Medical Expands Coatings and Additive Capacity
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login